Articles By Marcus Johnson
-
Boehringer Ingelheim Enters Production Agreement In Saudi Arabia With Cigalah and Tabuk
5/5/2014
Pharmaceutical giant Boehringer Ingelheim has entered into a local production agreement with Cigalah and Tabuk in Saudi Arabia. Boehringer Ingelheim has previously expressed interest in expanding into the Saudi Arabian market, and this deal will give the company a larger presence in the country as well as increase the amount of available treatment options in the Saudi Arabian market.
-
Novo Nordisk Awaiting FDA Approval Of Diabetes Drug For Weight Loss Treatment
5/2/2014
Novo Nordisk is seeking FDA approval of a new indication forits diabetes drug, liraglutide. Liraglutide is already approved as a diabetes drug, but Novo Nordisk has been testing liraglutide as a weight loss treatment, and results from a recent study suggest that the drug could reduce up to 10 percent of body mass.
-
Takeda To Increase Influenza Vaccine Production Capacity
5/2/2014
Takeda Pharmaceutical Company Limited has announced that the company will be receiving a subsidy from the Japanese government in order to expand its production capacity for influenza vaccines. The subsidy is significant, amounting to approximately 7.2 billion yen. Takeda will now enlarge the capacity of commercial vaccine facilities in Japan in order to provide the Japanese government with enough vaccines for another 8 million people. With the addition of another 8 million individuals’ worth of vaccines, the Japanese government will be able to cover about 33 million people in the event of a serious outbreak of influenza.
-
POZEN Receives FDA CRL Following Active Ingredient Supplier Facility Inspection
5/2/2014
Last week, POZEN announced that the company had received a complete response letter for its drug candidates PA8140/PA32540 (aspirin and omeprazole) delayed release tablets after the FDA after an inspection of one of POZEN’s manufacturing facilities.
-
Eli Lilly’s Stomach Cancer Drug Approved By The FDA
4/24/2014
Eli Lilly and Co. has announced that they will be putting their stomach cancer drug, Cyramza (ramucirumab), on the market after it received federal marketing approval by the FDA this past Monday. Industry analysts believe that the company is hoping that Cyramza will be able to replace the declining sales of several company drugs that recently lost their patent protection.
-
GSK And Novartis Agree On Asset Swap Worth Billions
4/23/2014
GlaxoSmithKline and Novartis have announced an asset swap deal worth billions. The two companies will combine multiple brands, including Aquafresh, Beechams, and Tixylix. They will also be swapping vaccines and oncology assets.
-
Bill Ackman, Valeant Pharmaceuticals Make $45.6 Billion Offer For Allergan Pharmaceuticals
4/23/2014
Bill Ackman, an activist Investor, has partnered with Canadian drug producer Valeant Pharmaceuticals in order to make a bid for Allergan.
-
AstraZeneca Rejects Pfizer Bid
4/23/2014
British pharmaceutical company AstraZeneca has rejected a merger offer from Pfizer.
-
Proposed California State Drug-Disposal Law Scrapped
4/21/2014
Last week, legislators killed the bill known as SB 1014 proposed by California state senator Hannah-Beth Jackson that would have required drug companies to create and finance a state-wide system for safely collecting and disposing of unwanted prescription drugs.
-
Price Of Specialty Drugs Increasing, Report Finds
4/21/2014
According to a new report released by the IMS Institute for Healthcare Informatics, the cost of specialty drugs will continue to increase.